Aurobindo Pharma reported a 61% rise in consolidated net profit to Rs 919 crore for Q1 ended June 2024, up from Rs 571 crore last year. Revenue increased to Rs 7,567 crore from Rs 6,851 crore. The growth was driven by strong sales and improved operational efficiencies.
